|
End-of-day quote
Korea S.E.
02/11/2026
|
5-day change | 1st Jan Change | ||
| 14,870.00 KRW | -0.13% |
|
-7.64% | -74.09% |
| 07-23 | Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell | MT |
| 12-22 | IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index | CI |
Company Valuation: IntoCell, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 |
|---|---|
| Market Cap 1 | 861,052 |
| Change | - |
| Enterprise Value (EV) 1 | 840,466 |
| Change | - |
| P/E | -77.1x |
| PBR | 34.8x |
| PEG | 48.66x |
| Capitalization / Revenue | 374,513,177x |
| EV / Revenue | - |
| EV / EBITDA | -88.2x |
| EV / EBIT | -81.6x |
| EV / FCF | -132x |
| FCF Yield | -0.76% |
| Dividend per Share 2 | - |
| Rate of return | - |
| EPS 2 | -744 |
| Distribution rate | - |
| Net sales | 2,299 |
| EBITDA 1 | -9,526 |
| EBIT 1 | -10,300 |
| Net income 1 | -10,603 |
| Net Debt 1 | -20,586 |
| Reference price 2 | 57,400.00 |
| Nbr of stocks (in thousands) | 15,001 |
| Announcement Date | 3/1/26 A |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 166M | |
| 16.47x | 6.17x | 11.83x | 1.81% | 62.23B | |
| 29.48x | 7.92x | 26.5x | 0.05% | 54.92B | |
| 37.71x | 6.69x | 19.98x | 0.86% | 55.26B | |
| 33.73x | 3.23x | 13.93x | -.--% | 42.59B | |
| 48.85x | 5.63x | 30.81x | -.--% | 41.08B | |
| -19.86x | 192.36x | -21.16x | -.--% | 40.33B | |
| 47.33x | 8.41x | 28.18x | -.--% | 33.12B | |
| 32.06x | 8.14x | 21.19x | 0.4% | 32.61B | |
| -68.85x | 12.63x | -70.58x | -.--% | 23.98B | |
| Average | 17.44x | 27.91x | 6.74x | 0.35% | 38.63B | |
| Weighted average by Cap. | 21.58x | 26.32x | 10.96x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A287840 Stock
- Valuation IntoCell, Inc.
Select your edition
All financial news and data tailored to specific country editions
